Pediatric Cancer Survivors Have 4-Fold Higher Risk of Death 40 Years After Diagnosis
From 15 to 40 years after diagnosis, pediatric cancer survivors have a roughly 4-fold higher risk of death than the general population, a study suggests.
From 15 to 40 years after diagnosis, pediatric cancer survivors have a roughly 4-fold higher risk of death than the general population, a study suggests.
The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS.
There are several factors that may increase the risk of thoracic soft tissue sarcoma in patients with a history of breast cancer.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake for Kaposi sarcoma.
Fyarro has also been added to the NCCN Guidelines as the only preferred treatment regimen for malignant PEComa.
Researchers sought to measure the risk of long-term neurocognitive outcomes in survivors of osteosarcoma and Ewing sarcoma.
The hospitalization rate was 49%, and 16% of patients died.
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
Young adults were more likely to receive chemotherapy.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.